The study evaluates the feasibility of using selected SNPs in diagnostics, disease prognosis, and the personalization of gynecological cancer therapies, including their role in predicting responses to treatments such as platinum-based chemotherapy and PARP inhibitors in the context of specific genetic profiles. Here, PARP1 is linked to female reproductive organ cancer.